Guess which ASX small cap stock is jumping on 'significant milestone'

This stock is ending the week in style. Let's see what is giving its shares a boost today.

| More on:
Six smiling health workers pose for a selfie.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Imugene Ltd (ASX: IMU) shares are ending the week on a positive note.

In late morning, trade, the ASX small cap stock is up 5% to 4.1 cents.

Why is this ASX small cap stock roaring higher?

Investors have been bidding the immuno-oncology company's shares higher on Friday after it released a clinical trial update.

This update relates to the phase 1b clinical trial of its allogeneic CAR T-cell therapy azer-cel at the Royal Prince Alfred Hospital (RPAH) in Sydney.

This trial is focused on patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), which is one of the most challenging and aggressive forms of non-Hodgkin's lymphoma.

According to the release, the first Australian patient has been dosed in the Phase 1b clinical trial at the RPAH.

It notes that azer-cel is one of the few allogeneic CAR T-cell therapies currently being evaluated in Australia. It offers an off-the-shelf alternative to traditional autologous CAR Tcell therapies, which require lengthy manufacturing processes involving a patient's own cells.

By utilising pre-manufactured donor T-cells, azer-cel has the potential to significantly shorten treatment timelines and expand accessibility for patients with limited options.

Promising data

The good news is that promising data has been reported recently from other trials.

The small cap ASX stock notes that it recently reported "promising data from its US trial sites, demonstrating the potential of azer-cel to deliver meaningful clinical outcomes."

In the US-based cohorts, three patients achieved complete responses (CR) despite having relapsed following multiple prior treatments, including autologous CAR T therapies.

It also notes that patients treated in Cohort B, which includes lymphodepletion chemotherapy and interleukin-2 (IL-2), have shown particularly robust and durable responses. This includes responses extending beyond 90 and 120 days.

'A significant milestone'

The small cap ASX stock's managing director and CEO, Leslie Chong, was very pleased with the news. Ms Chong said:

Achieving first patient dosed for azer-cel in Australia represents a significant milestone for Imugene and for Australian patients battling this devastating disease. The trial's opening at RPAH in Sydney reflects our commitment to accelerating the development of innovative, off the shelf immunotherapies that have the potential to improve outcomes for patients with relapsed or refractory DLBCL. We are proud to bring this trial to Australia and look forward to expanding recruitment across multiple sites.

Despite today's gain, this small cap remains down by a disappointing 65% over the past 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »